Barrow, Hanley, Mewhinney & Strauss
FOLD

Barrow, Hanley, Mewhinney & Strauss’s Amicus Therapeutics FOLD Stock Holding History

Barrow, Hanley, Mewhinney & Strauss’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-384
Closed -$2.2K – 362
2025
Q2 		$2.2K Buy
384
+218
+131% +$1.41K ﹤0.01% 291
2025
Q1 		$1.35K Buy
+166
New +$1.54K ﹤0.01% 291

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss's FOLD Position: Q3 2025 in Review

Barrow, Hanley, Mewhinney & Strauss sold out of Amicus Therapeutics (FOLD) in Q3 2025, closing a stake of 384 shares — an estimated $2.2K sold.

Barrow, Hanley, Mewhinney & Strauss first reported a position in FOLD in Q1 2025 and held it in 2 quarters. The position peaked at $2.2K in Q2 2025. 287 funds tracked by Wall St. Rank hold FOLD as of Q3 2025.

  • Barrow, Hanley, Mewhinney & Strauss reported no remaining Amicus Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Barrow, Hanley, Mewhinney & Strauss sold 384 Amicus Therapeutics shares in Q3 2025, an estimated $2.2K.
  • Barrow, Hanley, Mewhinney & Strauss first reported a position in Amicus Therapeutics in Q1 2025 and held it in 2 quarters.
  • Barrow, Hanley, Mewhinney & Strauss's Amicus Therapeutics position peaked at $2.2K in Q2 2025.
  • 287 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2025.

Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q3 2025, filed 13 Nov 2025.